Ozmosi | Alvocidib Drug Profile
Drug Search Results
Using advanced filters...
Advanced Search [+]

Alvocidib

Alternative Names: alvocidib, flavopiridol, flavopiridol (alvocidib)
Clinical Status: Inactive
Latest Update: 2024-03-01
Latest Update Note: PubMed Publication

Product Description

Alvocidib is a synthetic dihydroxyflavone that is 5,7-dihydroxyflavone which is substituted by a 3-hydroxy-1-methylpiperidin-4-yl group at position 8 and by a chlorine at the 2' position (the (-)-3S,4R stereoisomer). A cyclin-dependent kinase 9 (CDK9) inhibitor, it has been studied for the treatment of acute myeloid leukaemia, arthritis and atherosclerotic plaque formation. It has a role as an antineoplastic agent, an EC 2.7.11.22 (cyclin-dependent kinase) inhibitor, an antirheumatic drug and an apoptosis inducer. It is a dihydroxyflavone, a hydroxypiperidine, a member of monochlorobenzenes and a tertiary amino compound. It is a conjugate base of an alvocidib(1+). (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Alvocidib)

Mechanisms of Action: CDK9 Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Dainippon Sumitomo Pharma America
Company Location:
Company CEO:
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Phase 2: Thromboembolism|Head and Neck Cancer|Prolymphocytic Leukemia|Lymphocytic Chronic B-Cell Leukemia|Chronic Lymphoid Leukemia|Prolymphocytic B-Cell Leukemia|Squamous Cell Carcinoma|Multiple Myeloma|Peritoneal Cancer|Melanoma|Follicular Lymphoma|Multiple Sclerosis|Lymphoma, Non-Hodgkin|T-Cell Cutaneous Lymphoma|Lymphomatoid Granulomatosis|Large-Cell Immunoblastic Lymphoma|B-Cell Marginal Zone Lymphoma|Acute Myeloid Leukemia|Ovarian Cancer|Sezary Syndrome|Large-Cell Anaplastic Lymphoma|Immunoblastic Lymphadenopathy|Adult T-Cell Leukemia-Lymphoma|Mycosis Fungoides|Diffuse Large B-Cell Lymphoma|Pancreatic Cancer|Waldenstrom Macroglobulinemia|Mantle-Cell Lymphoma|Leukemia, Plasma Cell|Lymphoma, B-Cell|Adenocarcinoma|Renal Cell Carcinoma|Kidney Cancer|Liver Cancer|Esophageal Cancer|Breast Cancer|Endometrial Cancer|Sarcoma|Acute Megakaryoblastic Leukemia|Acute Erythroblastic Leukemia|Prostate Cancer|Myelodysplastic Syndrome|Preleukemia|Acute Basophilic Leukemia|Acute Myelomonocytic Leukemia|Gastrointestinal Cancer|Acute Lymphoid Leukemia|Seminoma|Germinoma|Acute Monocytic Leukemia|Testicular Cancer|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Acute Eosinophilic Leukemia|Hypereosinophilic Syndrome

Phase 1: Prolymphocytic B-Cell Leukemia|Thrombocytopenia|Anemia, Refractory|Chronic Lymphoid Leukemia|Lymphocytic Chronic B-Cell Leukemia|Adenocarcinoma|Acute Eosinophilic Leukemia|Acute Myelomonocytic Leukemia|Lymphoma, B-Cell|Prolymphocytic Leukemia|Chronic Myeloid Leukemia|Blast Crisis|Acute Lymphoid Leukemia|Pancreatic Cancer|Neuroblastoma|Lymphoma, Non-Hodgkin|Oncology Solid Tumor Unspecified|Astrocytoma|Osteosarcoma|Medulloblastoma|Embryonal Rhabdomyosarcoma|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Liver Cancer|Hypothalamic Cancer|Kidney Cancer|Brain Stem Cancer|Wilms Tumor|Acute Basophilic Leukemia|Acute Myeloid Leukemia|Acute Megakaryoblastic Leukemia|Male Breast Cancer|Acute Erythroblastic Leukemia|Leukemia|Chronic Myelomonocytic Leukemia|Hypereosinophilic Syndrome|Acute Monocytic Leukemia|Myelogenous, Chronic, BCR-ABL Positive Leukemia|Sarcoma, Ewing|Retinoblastoma|Optic Nerve Cancer|Optic Nerve Glioma|Cerebellar Cancer|Prostate Cancer|Primitive Neuroectodermal Tumors|Supratentorial Cancer|Soft Tissue Cancer|Lymphoid Leukemia|Peripheral Neuroectodermal Tumors, Primitive|Ependymoma|Kidney Diseases|Intestinal Cancer|Lymphoma|Non-Small-Cell Lung Cancer|Esophageal Cancer|Follicular Lymphoma|Diffuse Large B-Cell Lymphoma|Mesothelioma|Melanoma|Anemia, Refractory, with Excess of Blasts|Mantle-Cell Lymphoma|Waldenstrom Macroglobulinemia|Hairy Cell Leukemia|Lymphoproliferative Disorders|Multiple Myeloma|Breast Cancer|Skin Cancer|B-Cell Marginal Zone Lymphoma|Sarcoma|Gastrointestinal Stromal Tumors|Oncology Hematological Unspecified

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

NCT03441555

M16-186

P1

Completed

Acute Myeloid Leukemia

2021-01-25

25%

2023-10-18

Primary Endpoints|Treatments

NCT03563560

AML

P1

Completed

Acute Myeloid Leukemia

2020-03-31

32%

2024-11-27

Primary Endpoints|Treatments

JapicCTI-183964

JapicCTI-183964

P1

Unknown

Acute Myeloid Leukemia

2020-03-31

NCT03298984

TPI-ALV-101

P1

Completed

Acute Myeloid Leukemia

2020-03-20

16%

2024-11-27

Primary Endpoints|Treatments

NCT00094978

05-C-0010

P1

Terminated

Non-Small-Cell Lung Cancer|Mesothelioma|Esophageal Cancer

2013-05-20

2019-03-21

Treatments

NCT00735930

NCI-2009-00269

P1

Completed

Anemia, Refractory|Thrombocytopenia|Chronic Lymphoid Leukemia|Lymphocytic Chronic B-Cell Leukemia|Lymphoma, B-Cell|Prolymphocytic Leukemia|Prolymphocytic B-Cell Leukemia

2013-03-01

2019-03-18

Treatments

NCT00101231

NCI-2012-01461

P1

Terminated

Acute Lymphoid Leukemia|Blast Crisis|Hypereosinophilic Syndrome|Acute Myelomonocytic Leukemia|Acute Monocytic Leukemia|Chronic Lymphoid Leukemia|Acute Basophilic Leukemia|Acute Eosinophilic Leukemia|Myelogenous, Chronic, BCR-ABL Positive Leukemia|Chronic Myeloid Leukemia|Acute Myeloid Leukemia|Chronic Myelomonocytic Leukemia|Acute Erythroblastic Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Acute Megakaryoblastic Leukemia

2012-11-01

2019-03-21

Treatments

NCT00377104

NCI-2009-00161

P1

Terminated

Lymphoma, B-Cell|Chronic Lymphoid Leukemia|Lymphocytic Chronic B-Cell Leukemia

2012-11-01

2019-03-21

Treatments

NCT00082784

NCI-2009-00058

P1

Completed

B-Cell Marginal Zone Lymphoma|Diffuse Large B-Cell Lymphoma|Multiple Myeloma|Lymphoma, Non-Hodgkin|Follicular Lymphoma|Waldenstrom Macroglobulinemia|Mantle-Cell Lymphoma

2012-10-01

2019-03-21

Treatments

NCT00112684

NCI-2009-00135

P1

Terminated

Oncology Solid Tumor Unspecified

2012-07-01

2019-03-21

Treatments

NCT00098579

NCI-2009-00048

P1

Completed

Sarcoma|Gastrointestinal Stromal Tumors

2011-07-01

2024-11-27

Primary Endpoints|Treatments

NCT00470197

NCI-2009-00243

P1

Completed

Acute Myelomonocytic Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Acute Megakaryoblastic Leukemia|Acute Monocytic Leukemia|Acute Myeloid Leukemia|Acute Lymphoid Leukemia|Acute Erythroblastic Leukemia

2011-01-01

2024-11-27

2017-001178-41

2017-001178-41

P2

Terminated

Acute Myeloid Leukemia

2021-10-10

2022-03-13

Treatments

NCT03593915

TPI-ALV-102

P2

Terminated

Preleukemia|Myelodysplastic Syndrome

2021-08-16

13%

2023-10-18

Primary Endpoints

NCT03969420

TPI-ALV-202

P2

Terminated

Acute Myeloid Leukemia

2021-04-22

36%

2023-10-18

NCT04493099

NCI-2020-05266

P2

Withdrawn

Acute Myeloid Leukemia

2020-10-12

2020-11-13

NCT02520011

TPI-ALV-201

P2

Terminated

Acute Myeloid Leukemia

2020-02-12

70%

2024-11-27

Primary Endpoints

NCT00634244

NCI-2009-00520

P2

Completed

Acute Erythroblastic Leukemia|Acute Myeloid Leukemia|Acute Monocytic Leukemia|Acute Myelomonocytic Leukemia|Acute Megakaryoblastic Leukemia

2014-09-01

2024-11-27

Primary Endpoints|Treatments

NCT00957905

NCI-2011-01405

P2

Completed

Testicular Cancer|Ovarian Cancer|Seminoma|Germinoma

2014-08-01

2025-02-07

Primary Endpoints|Treatments

NCT01349972

NCI-2011-02587

P2

Completed

Myelodysplastic Syndrome|Acute Monocytic Leukemia|Acute Erythroblastic Leukemia|Acute Myeloid Leukemia|Acute Myelomonocytic Leukemia

2014-05-01

2024-11-27

Primary Endpoints|Treatments

NCT00445341

07-C-0081

P2

Completed

Diffuse Large B-Cell Lymphoma|Mantle-Cell Lymphoma

2012-04-30

2019-03-21

NCT00991952

NCI-2011-03825

P2

Completed

Gastrointestinal Cancer|Adenocarcinoma|Esophageal Cancer

2012-02-01

2024-11-27

Primary Endpoints|Treatments

2006-006152-34

2006-006152-34

P2

Completed

Prolymphocytic B-Cell Leukemia|Prolymphocytic Leukemia|Chronic Lymphoid Leukemia|Lymphocytic Chronic B-Cell Leukemia

2012-01-16

2022-03-12

Treatments

NCT00464633

EFC6663

P2

Completed

Chronic Lymphoid Leukemia|Prolymphocytic B-Cell Leukemia|Lymphocytic Chronic B-Cell Leukemia|Prolymphocytic Leukemia

2011-12-01

2019-03-21

Treatments

NCT00112723

NCI-2011-01346

P2

Terminated

Immunoblastic Lymphadenopathy|Sezary Syndrome|Large-Cell Anaplastic Lymphoma|T-Cell Cutaneous Lymphoma|Lymphoma, Non-Hodgkin|Adult T-Cell Leukemia-Lymphoma|Mycosis Fungoides|B-Cell Marginal Zone Lymphoma|Large-Cell Immunoblastic Lymphoma|Lymphomatoid Granulomatosis|Lymphocytic Chronic B-Cell Leukemia|Follicular Lymphoma|Multiple Myeloma|Waldenstrom Macroglobulinemia|Multiple Sclerosis|Mantle-Cell Lymphoma|Leukemia, Plasma Cell|Diffuse Large B-Cell Lymphoma|Chronic Lymphoid Leukemia

2011-02-01

2020-10-26

Primary Endpoints